Discordance Between Genotypic and Phenotypic Methods for the Detection of Rifampicin and Isoniazid Resistant and the Correlation with Patient Treatment Outcomes

Overview

Journal J Clin Tuberc Other Mycobact Dis

Date 2024 Jan 16

PMID 38225941

Authors

Zegeye Bonsa

Mulualem Tadesse

Getu Balay

Wakjira Kebede

Gemeda Abebe

Affiliations

Soon will be listed here.

Abstract

Background: Accurate drug susceptibility testing (DST) of (MTB) is essential for proper patient management. We investigated discordance between genotypic (Xpert MTB/RIF and MTBDR) and phenotypic (MGIT 960) methods for the detection of rifampicin (RIF) and isoniazid (INH) resistant MTB and its correlation with patient treatment outcomes in Jimma, Southwest Oromia, Ethiopia.

Methods: A retrospective study was conducted on 57 stored MTB isolates with known Xpert RIF resistance status (45 RIF resistant and 12 RIF susceptible) at Jimma University Mycobacteriology Research Center from November 2, 2021, to December 28, 2022. We did MTBDR and phenotypic DST (using the Mycobacterial Growth Indicator Tube (MGIT) system). The Xpert and MTBDR results were compared using phenotypic DST as a reference standard method. The treatment outcome was determined as per national guideline. The discordance between the genotypic and phenotypic DST was calculated using GraphPad software.

Results: Among the 57 MTB isolates, six (10.5 %) had discordant results between the two DST methods. Xpert yielded five discordant results for RIF when compared with phenotypic DST (kappa coefficient (κ) = 0.76, 95 % confidence interval 0.56-0.96). The MTBDR compared with phenotypic DST gave three discordant results for RIF (κ = 0.86, 95 % confidence interval 0.71-1.00) and three for INH (κ = 0.86, 95 % confidence interval 0.70-1.00). Compared with Xpert, MTBDR yielded lower discordance with phenotypic DST for RIF. Out of six patients with discordant results, three had unfavorable outcomes while the other three were cured. Of the three patients with unfavorable outcomes, only one patient has received an inappropriate treatment regimen. There was no correlation between unfavorable outcomes and incorrect treatment regimens due to discordant results (Χ = 0.404; P = 0.525).

Conclusions: Discordance between genotypic and phenotypic DST for RIF or INH occurred in 10.5 % of isolates. Only one patient with discordant results has received an inappropriate treatment regimen, resulting in an unfavorable outcome. The impact of parallel use of rapid molecular assay with phenotypic DST on patient treatment outcomes requires further study.

Citing Articles

Pretreatment attrition after rifampicin-resistant tuberculosis diagnosis with Xpert MTB/RIF or ultra in high TB burden countries: a systematic review and meta-analysis.

Jouego C, Decroo T, Netongo P, Gils T BMJ Glob Health. 2025; 10(1).

PMID: 39848636 PMC: 11758687. DOI: 10.1136/bmjgh-2024-015977.

Evaluation of extracts from used Xpert MTB/RIF cartridges for detection of resistance to second-line anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis in Ethiopia.

Ketema T, Tadesse M, Bonsa Z, Balay G, Kebede W, Mekonnen M BMC Microbiol. 2025; 25(1):26.

PMID: 39825226 PMC: 11740401. DOI: 10.1186/s12866-025-03746-6.

References

Moga S, Bobosha K, Fikadu D, Zerihun B, Diriba G, Amare M . Diagnostic performance of the GenoType MTBDRplus VER 2.0 line probe assay for the detection of isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS One. 2023; 18(4):e0284737. PMC: 10132600. DOI: 10.1371/journal.pone.0284737. View

Helmy M, Awad M, Mosa K . Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genom. 2016; 9:15-9. PMC: 4911431. DOI: 10.1016/j.atg.2016.03.003. View

Alonso M, Palacios J, Herranz M, Penedo A, Menendez A, Bouza E . Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol. 2011; 49(7):2688-90. PMC: 3147855. DOI: 10.1128/JCM.00659-11. View

Moure R, Martin R, Alcaide F . Silent mutation in rpoB detected from clinical samples with rifampin-susceptible Mycobacterium tuberculosis. J Clin Microbiol. 2011; 49(10):3722. PMC: 3187328. DOI: 10.1128/JCM.05314-11. View

Berhanu R, Schnippel K, Kularatne R, Firnhaber C, Jacobson K, Horsburgh C . Discordant rifampicin susceptibility results are associated with Xpert MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019; 23(3):358-362. PMC: 6495054. DOI: 10.5588/ijtld.16.0837. View

Hu P, Zhang H, Fleming J, Zhu G, Zhang S, Wang Y . Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China. J Clin Microbiol. 2019; 57(4). PMC: 6440781. DOI: 10.1128/JCM.01707-18. View

Wondale B, Medhin G, Abebe G, Tolosa S, Mohammed T, Teklu T . Phenotypic and genotypic drug sensitivity of complex isolated from South Omo Zone, Southern Ethiopia. Infect Drug Resist. 2018; 11:1581-1589. PMC: 6161742. DOI: 10.2147/IDR.S165088. View

Ngabonziza J, Decroo T, Migambi P, Habimana Y, Van Deun A, Meehan C . Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe. 2022; 1(2):e74-e83. DOI: 10.1016/S2666-5247(20)30007-0. View

Zurcher K, Ballif M, Fenner L, Borrell S, Keller P, Gnokoro J . Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis. 2019; 19(3):298-307. PMC: 6482382. DOI: 10.1016/S1473-3099(18)30673-X. View

10.

Tola A, Mishore K, Ayele Y, Mekuria A, Legese N . Treatment Outcome of Tuberculosis and Associated Factors among TB-HIV Co-Infected Patients at Public Hospitals of Harar Town, Eastern Ethiopia. A five-year retrospective study. BMC Public Health. 2019; 19(1):1658. PMC: 6902430. DOI: 10.1186/s12889-019-7980-x. View

11.

Sinshaw Y, Alemu S, Fekadu A, Gizachew M . Successful TB treatment outcome and its associated factors among TB/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional study. BMC Infect Dis. 2017; 17(1):132. PMC: 5299781. DOI: 10.1186/s12879-017-2238-7. View

12.

Noor K, Shephard L, Bastian I . Molecular diagnostics for tuberculosis. Pathology. 2015; 47(3):250-6. DOI: 10.1097/PAT.0000000000000232. View

13.

Mvelase N, Cele L, Singh R, Naidoo Y, Giandhari J, Wilkinson E . Consequences of mutations missed by the GenoType MTBDR assay in a programmatic setting in South Africa. Afr J Lab Med. 2023; 12(1):1975. PMC: 9982466. DOI: 10.4102/ajlm.v12i1.1975. View

14.

Al-Mutairi N, Ahmad S, Mokaddas E, Eldeen H, Joseph S . Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis. 2019; 19(1):3. PMC: 6318973. DOI: 10.1186/s12879-018-3638-z. View

15.

Walker T, Kohl T, Omar S, Hedge J, Del Ojo Elias C, Bradley P . Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015; 15(10):1193-1202. PMC: 4579482. DOI: 10.1016/S1473-3099(15)00062-6. View

16.

Rifat D, Campodonico V, Tao J, Miller J, Alp A, Yao Y . In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D. Future Microbiol. 2017; 12:753-765. PMC: 5506874. DOI: 10.2217/fmb-2017-0022. View

17.

Worku G, Gumi B, Girma M, Mohammedbirhan B, Diriba G, Seid G . Drug sensitivity of clinical isolates of and its association with bacterial genotype in the Somali region, Eastern Ethiopia. Front Public Health. 2022; 10:942618. PMC: 9428271. DOI: 10.3389/fpubh.2022.942618. View

18.

Reta M, Tamene B, Abate B, Mensah E, Maningi N, Fourie P . Drug Resistance in Ethiopia: An Updated Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2022; 7(10). PMC: 9611116. DOI: 10.3390/tropicalmed7100300. View

19.

Akalu G, Tessema B, Petros B . High proportion of RR-TB and mutations conferring RR outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive pulmonary tuberculosis cases, in Addis Ababa, Ethiopia. PLoS One. 2022; 17(12):e0277145. PMC: 9803184. DOI: 10.1371/journal.pone.0277145. View

20.

Jagielski T, Bakula Z, Roeske K, Kaminski M, Napiorkowska A, Augustynowicz-Kopec E . Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2015; 70(12):3214-21. DOI: 10.1093/jac/dkv253. View